Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOLUMA
NCT03083691Phase 2Completed
- Sponsor
- Lung Cancer Group Cologne
- Start
- Apr 2017
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 cohorts), sponsored by Lung Cancer Group Cologne. Primary endpoint: Overall Response Rate up to 120 months. Started Apr 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03083691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083691.